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Since the disclosure of Biginelli reaction by the chemist Pietro Biginelli, functionalized 3,4-dihy-
dropyrimidin-2(1H)-ones/thiones (DHPMs) have emerged as prototypes for the design of
compounds with a broad variety of biological activities. This mini-review describes over 100
Biginelli adducts demonstrated to be promising anticancer, inhibitors of calcium channel,
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The year 1891 was a milestone for the discovery of a new class
of heterocycle molecules named Biginelli adducts after the
chemist Pietro Biginelli who ﬁrst report the simple one-pot
process that furnish organic compounds of this kind [1]. The
multicomponent reaction that provides Biginelli adducts, also
NN
R3
R4
R5
X
R2
R1
X = O, NH or S
R1-5 = H, alkyl, aryl, ester, amide, acyl,
(thio)urea or an heterocycle
Fig. 1 Basic structure of Biginelli adducts.
Biginelli adducts and biological activities 365known as 3,4-dihydropyrimidin-2(1H)-ones/thiones (DHPMs;
Fig. 1), involves the reaction of 1,3-dicarbonyl compounds
with aldehydes and (thio)urea [2]. Three main mechanisms
have been proposed for the Biginelli reaction, but this subject
is still under debate in the literature. Detailed information on
these three mechanisms is addressed elsewhere [3]. Variation
of all three building blocks has broadened the molecular
diversity of DHPMs with wide variety biological activities.
Indeed, a series of pharmacological properties of DHPMs have
been reported, which include antiviral, antitumor, anti-inﬂam-
matory, antibacterial, antifungal, anti-epileptic, antimalarial,
antileishmanial, among others. The next topics will cover for
some of the most notable Biginelli adducts reported as antican-
cer, calcium channel inhibitors, anti-inﬂammatory, antimicro-
bial and antioxidant agents since the listed pharmacological
properties are some of the most investigated for DHPMs.HN
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Fig. 2 Example of Biginelli adducts that possessAnticancer activity
Biginelli adducts are promising compounds for the treatment
of cancers in which monastrol (1) is the most studied with this
regard (Fig. 2). The ﬁrst work that explored the effect of
monastrol on cancer cells was reported in 1999 [4].
Monastrol was found to interrupt mitosis by inhibiting the
motor activity of the kinesin Eg5, a protein involved in spindle
bipolarity formation [5].
Since then, monastrol has been used as an inspiration for
the design of new anticancer agents. Out of eleven monastrol
analogues synthesized, the Biginelli adduct 2 was identiﬁed
as a potent anticancer agent based on the concentration of this
adduct necessary to inhibit cell growth by 50% (EC50, IC50 or
GI50) as it follows: MCF-7 breast (1.9 lg mL
1), 786-0 kidney
(2.0 lg mL1), HT-29 colon (2.5 lg mL1), UACC.62 mela-
noma (6.0 lg mL1) and OVCAR03 ovarian (6.6 lg mL1)
cancer cells [5].
Compounds 3–10 (Fig. 2) were described as some of the
most effective pyrimidinone-peptoid hybrids against SK-BR-
3 breast cancer cells, exhibiting GI50 values in the range of
6.0–8.8 lM [6].
Biginelli adducts bearing cinnamoyl (11 and 12), pyridin-4-
yl (13) or furan-2-yl (14 and 15) groups (Fig. 2) showed signif-
icant cytotoxic effects against the MCF-7 breast cancer cell
line, in which at concentration of 50 lg mL1 prevented cell
growth by at least 70% [7].N
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antiproliferative activity against cancer cells.
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Fig. 3 Other examples of Biginelli adducts well-known for their ability to inhibit cancer cells growth.
Table 1 Potency (in folds) of Biginelli adducts relative to monastrol (1) with respect to the antiproliferative activity against cancer
cells of different histological origins. Adapted from da Silva and coworkers [9].
Biginelli adduct U251 NCI-ADR/RES 786-0 NCI-H460 PC-3 OVCAR-03 HT-29
19 96.0 10.6 (–) (–) (–) 9.0 (–)
20 5.0 88.8 (–) (–) (–) 8.4 1.0
21 31.0 1.0 (–) (–) (–) 7.5 1.0
22 1.0 7.0 (–) (–) 1.0 14.3 1.0
23 1.0 1.0 1.0 3.0 11.0 6.5 1.0
24 5.7 7.0 (–) (–) (–) (–) 1.0
25 1.0 1.0 (–) (–) (–) 11.0 1.0
26 4.7 2.0 (–) (–) (–) 2.4 1.0
27 (–) 4.0 (–) (–) (–) (–) 1.0
28 3.0 8.0 1.5 3.0 (–) 1.4 3.0
29 4.0 (–) (–) (–) (–) 1.7 1.7
30 1.0 6.0 (–) (–) 3.0 (–) 1.0
GI50 values for monastrol were in range of 4.0–29.6 lg mL
1 [9]. (–) Indicates that the Biginelli adduct was less potent than monastrol (1). U251,
glioma cells; NCI-ADR/RES, multiple drug-resistant ovarian cancer cells; 786, renal cancer cells; NCI-H460, non-small lung cancer cells; PC-3,
prostate cancer cells; OVCAR-03, ovarian cancer cells and HT-29, colon cancer cells.
366 Aˆ. de Fa´tima et al.Biginelli adducts-amide derivatives such as 16 and 17
(Fig. 3) exhibited moderate antiproliferative activity against
HepG2 epithelial carcinoma in which the IC50 value for
both compounds was ca. 120 lg mL1 [8]. On the other hand,
the derivatives 17 and 18 showed IC50 values of around
190 lg mL1 against HeLa hepatocellular carcinoma cells
[8].
Other monastrol (1) analogues were synthesized and tested
against cancer cell lines of different histological origins [9].
Twelve Biginelli adducts (19–30; Fig. 3) were more potent than
monastrol (GI50 in the range of 4.0–29.6 lg mL
1) against one
or more of the seven cancer cell lines studied (Table 1) [9].
Notably, compound 19 was determined to be over 90- and
10-fold more potent than monastrol (1) against U251 glioma
cells and NCI-ADR/RES multiple drug-resistant ovarian
cancer cells, respectively (Table 1). Compound 20 was foundto be almost 90-fold more potent than monastrol against
NCI-ADR/RES multiple drug-resistant ovarian cancer cells
while the GI50 value for 21 is about 30-fold lower than that
of monastrol toward U251 cells (Table 1). The results also
indicate that six Biginelli adducts present GI50 values at least
5-fold lower than those of monastrol against some of the
following cancer cells: U251 glioma, NCI-ADR/RES multiple
drug-resistant ovarian, 786 renal, NCI-H460 non-small lung,
PC-3 prostate, OVCAR-03 ovarian and HT-29 colon cancer
(Table 1).
Morphological alterations in MCF-7 breast cancer cells
that culminated in the death of over 80% cells were observed
after 72 h of treatment with the Biginelli adducts 31 (dimethy-
lenastron) to 33 (Fig. 3) at concentrations in the range of
400 lM to 1 mM. Such compounds showed minute toxic
effects against ﬁbroblast healthy cells [10].
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Fig. 4 Example of Biginelli adducts that exhibit inhibitory effect on calcium channels.
Biginelli adducts and biological activities 367Calcium channel inhibition
Dihydropyridines such as nifedipine were introduced to the
market in 1975 for the treatment of cardiovascular diseases
(hypertension, cardiac arrhythmias and angina) due to the
ability to inhibit calcium channels [11]. After the discovery of
this drug several analogues, including Biginelli adducts, were
synthesized to verify the potential to block calcium channels.
A structure–activity relationship study with Biginelli
adducts was reported in 1990 with respect to the ability to
target calcium channels [12,13]. It was determined that thio-
adducts were the most potent Biginelli compounds in compar-
ison with oxo- and aza-analogues [12,13]. In vitro assays
revealed that the adduct bearing a nitro group at ortho-
position of aromatic ring was more effective antihypertensive
compound than that containing CF3 or Cl as substituent
(Fig. 4) [13]. Interestingly, the presence of an isopropyl ester
group at C5 improved the Biginelli adduct potency by 10-
and 60-fold in comparison with the effect of the ones bearing
an ethyl ester or methyl ester group at the same carbon,
respectively [13]. Although compounds bearing substituents
at N3 are potent calcium channel blockers in vitro, their anti-
hypertensive properties are lost in in vivo experiments as a
result of metabolization by rats [13]. Additionally, oxo-ana-
logues were found to be more stable as homogenates fromrat liver did not present metabolites derived from such these
compounds [13]. Finally, the stereocenter at C4 also plays a
key role in the activity of such Biginelli adducts toward cal-
cium channel; the (R)-enantiomer (34a; Fig. 4) is 750-fold
more potent vasorelaxant agent than the corresponding (S)-
enantiomer (34b; Fig. 4) [13]. Atwal and coworkers then
substituted the acyl at N3 for a carbamoyl group to check
whether such structural changes would affect the inhibition
of calcium channel by Biginelli adducts related to 34 [14].
The best compounds (35–39; Fig. 4) tested in vitro exhibited
IC50 values of 3, 12, 13, 16 and 60 nM, respectively. Thus, it
was concluded that the presence of substituents at carbamoyl
group inﬂuenced compounds potency as it follows: benzyl
group > hydrogen, methyl or ethyl group > isopropyl group
[14]. Compounds bearing 1-(phenylmethyl)-4-piperidinyl car-
bamate at N3 were described as the most promising calcium
channel blockers in in vivo experiments, in which the presence
of CF3 at ortho-position of aromatic ring enhanced com-
pounds effect when compared to the ones bearing nitro group
[15]. Additionally, ﬂuorine at para-position of benzyl moiety
prevented the Biginelli adduct from metabolization by rat cells
and conferred much higher potency than that of the reference
drug amlodipine. Again, in vitro experiments demonstrated
that the (R)-enantiomer (40a; Fig. 4) is much more potent than
the corresponding (S)-enantiomer (40b; Fig. 4), since the
368 Aˆ. de Fa´tima et al.former exhibits an IC50 value of 15 nM while the IC50 value for
the latter is determined to be higher than 1000 nM [15].
The thio-Biginelli adducts 41 and 42 were determined to be
relaxant agents as effective as the reference drug nicardipine
(inhibition of stimulus by 35.5 ± 4.2%) on KCl-stimulated
lamb carotid strips when used at 100 lM [16]. Compounds
41 and 42 present a Cl atom as substituent at meta- and
para-position, respectively (Fig. 4). The relaxant effect of the
thio-Biginelli adduct 43 (Fig. 4) on KCl-stimulated contractions
in rat thoracic aorta was comparable to that of nicardipine
(inhibition of stimulus by 20.5 ± 2.9%) [17]. Other oxo-
Biginelli adducts were investigated for the calcium channel
blockage-dependent relaxant effect on KCl-stimulated lamb
carotid strips. Compounds containing Br, CH3 or CF3 at
ortho-position or Br at meta-position in aromatic ring (44–
47; Fig. 4) at 1 lM were either as potent or as more potent
than nicardipine that at the same concentration was able to
inhibit the stimulus by 2.5 ± 1.8% [18].
The acetylated thio-Biginelli adduct derivative 48 (Fig. 4)
effectively caused the relaxation of KCl-stimulated guinea
pig ileum as attested by its value of negative log molar concen-
tration of antagonist required to reduce the response of agonist
by 50% (PA2 = 6.06) in relation to the reference drug
verapamil [19].
Anti-inﬂammatory activity
Inﬂammation process can be characterized by ﬁve phases that
may or may not occur simultaneously, named pain, heat, red-
ness, swelling and ultimately loss of function. They comprise a
defensive body response to invasion of a foreign material.
Acute inﬂammation can cause several damages in tissues orFig. 5 Example of Biginelli adducts thorgans. The anti-inﬂammatory potential of a certain molecule
can be investigated by various means, such as the analgesic
effect using paw edema as model, the inhibition of proinﬂam-
matory cytokines (e.g. tumor necrosis factor (TNF-a) and
interleukin 6 (IL-6)) [20], the effect on prostaglandin E2 and/
or hialuronidase, nitric oxide synthase (iNOS) and
cyclooxygenase-2 (COX-2) and transient receptor A1
(TRPA1), among others [20–24].
Biginelli adducts have received great attention with respect
to their potential as anti-inﬂammatory agents. Based on the
duration of action and percentage of inﬂammation inhibition
on Albino rats paw edema, the propanoic acid derivatives
thio-adducts (49–53; Fig. 5) were found to be the most
promising anti-inﬂammatory compounds when compared to
diclofenac, a reference drug [25]. The Biginelli derivative 54,
which bears a 1,3,4-oxadiazol-2-yl moiety (Fig. 5), controls
inﬂammation process by inhibiting the carrageenan-induced
rat paw edema by 75% after 3 h of treatment, an effect
comparable to that exhibited by diclofenac [26].
The potential of the thio-analogue Biginelli adduct 55
(Fig. 5) to inhibit the production of proinﬂammatory
cytokines in LPS-induced human monocytic leukemia cells
(THP-1) was addressed [20]. The production of TNF-a and
IL-6 in THP-1 cells in the presence of compound 55 at
10 lM was 78% and 96% lower than that of cells incubated
in the absence of this Biginelli adduct, respectively. Under
the same experimental conditions, dexamethasone (reference
drug at 1 lM) inhibit TNF-a and IL-6 production by 71%
and 84%, respectively [20].
Chronic inﬂammation is known to be associated with
increased activity of hyaluronidases, enzymes that catalyzes
the degradation of hyaluronic acid [27,28]. Based on this,at exhibit anti-inﬂammatory effect.
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Fig. 6 Example of Biginelli adducts that exhibit antimicrobial activity.
Biginelli adducts and biological activities 369Gireesh and coworkers performed molecular docking studies
using some Biginelli adducts and related derivatives to identify
compounds with potential to inhibit hyaluronidase [24].
Indeed, in vitro assays conﬁrmed that 100 lg of compounds
56–59 (Fig. 5) was able to inhibit the activity of hyaluronidase
(3–5 units) in the range from 89% to 100%. Similar results
were achieved when compounds 56–59 were substituted for
indomethacin, a reference drug [24].
The anti-inﬂammatory properties of Biginelli adducts 60–
62 (Fig. 5) were attested by their capacity to inhibit NO
production in LPS-activated microglia at IC50 values ranging
from 41.3 to 67.3 lM [29]. Compound 60 was also the most
potent among these Biginelli adducts in the inhibition of pros-
taglandin E2 (PGE2) production and iNOS and COX-2 genes
expression. Additionally, 60 negatively affected the production
of TNFa and interleukin-1 b (IL-1b) [23].
Biginelli adducts bearing meta-substituents have been
described as very promising anti-inﬂammatory agents in stud-
ies carried out with human embryonic kidney 293 cell lines
(HEK293) overexpressing the transient receptor potential A1
(TRPA1) either from human or rat [22]. Thus, compounds
63a-b and 64a-b (Fig. 5) were able to inhibit both humanand rat TRPA1 at concentrations ranging from 4 to 75 nM.
The R isomers (63b and 64b), however, were identiﬁed as the
most potent inhibitors acting on rat TRPA1 at IC50 values
as low as 4 and 12 nM, respectively, while the IC50 for the
corresponding S isomers (63c and 64c; Fig. 5) were found to
be higher than 10,000 nM [22].
Antibacterial activity
Biginelli compounds bearing a 1,3-diarylpyrazole moiety (65–
68; Fig. 6) exhibited minimal inhibition concentration (MIC)
of 20 ng mL1, 20 ng mL1, 250 ng mL1 and 125 ng mL1
against the Mycobacterium tuberculosis H37Rv (MTB
H37Rv), respectively [30,31]. The effect of 65 and 66 on normal
kidney-derived African green monkey cells (VERO line) was
assessed, revealing that both Biginelli adducts are highly selec-
tive to MTB H37Rv (selectivity index >500) [30]. Other 16
Biginelli adducts (69–74; Fig. 6) were found to be as potent
as or more potent than the reference drugs ethambutol
(MIC = 7.6 lM) and ciproﬂoxacin (MIC = 9.4 lM) against
MTB H37Rv. The MIC values for compounds 69–74 ranged
from 3.4 to 76.2 lM [32].
370 Aˆ. de Fa´tima et al.Compounds 75 and 76, containing a nitro group and ﬂuo-
rine at para-position, respectively, exhibited MIC values of
12.5 lg mL1 (for the former) and 12.5–25.0 lg mL1 (for
the latter) against Escherichia coli, Klebsiella pneumonia,
Pseudomonas aeruginosa, Salmonella typhi and
Staphylococcus aureus, which make these compounds more
potent than ciproﬂoxacin [33]. Biginelli adducts bearing a
1,3-dihydro-2H-indol-2-one core showed moderate antibacte-
rial activities (62.5–250.0 lg mL1) against Bacillus subtilis
(MTCC-441), E. coli (MTCC-443), K. pneumonia (MTCC-
109), P. aeruginosa (MTCC-1688), S. typhi (MTCC-98), S.
aureus (MTCC-96) and Staphylococcus pyogenus (MTCC-
442) [34].
Antiviral activity
Kim and coworkers showed the potential of some Biginelli
adducts as agents for preventing human immunodeﬁciency
virus HIV-1 replication [35,36]. Notably, compounds 77–82
(Fig. 6) compromised the HIV-1 replication in CEMx174-
LTR-GFP cells (clone CG8) by 50% when employed at
concentrations lower than 90 nM. At the same experimental
conditions, the reference drug nevirapine exhibited an EC50
value of 150 nM [35,36]. The (S)-enantiomer was determined
to be more potent than the corresponding (R)-enantiomer with
respect to the antiviral activity. Indeed, it was shown that (S)-77
is at least 26-fold more potent than (R)-77 [35,36].
The potential of the Biginelli-type pyrimidines 83
(IC50 = 1.8 lM) and 84 (IC50 = 0.9 lM) against herpes sim-
plex virus (HSV-KOS strain) was shown elsewhere (Fig. 6)
[37]. Notably, the analogue 84 exhibited negligible toxicity
toward the mammalian cells tested indicating its selectivity to
the studied virus. A time-of-addition study was then performed
with 84 revealing that the administration of such compound to
cells 2 and 4 h post inoculation was sufﬁcient to negatively
affect virus replication. The lack of inhibition of virus adhesion
and/or entry to the cells suggests that compound 84 inhibits
virus replication in late stages [37].N
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Fig. 7 Example of Biginelli adducts with ability toAntifungal activity
Fungi have emerged worldwide as some of the most frequent
causes of healthcare-associated infections. Invasive fungal
infections can be life-threatening and the number of antifungal
agents currently available in the market is very limited [38].
Although Biginelli adducts have been poorly explored with
respect to the antifungal activity, some examples of promising
compounds are described in the literature. Eleven Biginelli-
type pyrimido[4,5-d]pyrimidine-2,5-diones were described as
potential anti-Aspergillus niger and anti-Candida albicans
agents, exhibiting MIC values raging from 11 to 57 lg mL1
[39]. The most active compounds (85–88; Fig. 6) showed
MIC values near to or lower than 20 lg mL1 in comparison
with the reference antifungal clotrimazole, whose MIC values
against A. niger and C. albicans were 20 and 25 lg mL1,
respectively. Thus, analogues bearing withdrawing groups,
with exception of 4-Cl substituent, were the most active against
A. niger and C. albicans [39].
The Biginelli adducts 75 and 76 (Fig. 6) efﬁciently inhibited
the growth of C. albicans, Aspergillus ﬂavus, Rhizopus sp. and
Mucor sp. as attested by the MIC values in the range of 12.5–
25 lg mL1, being most of the time more potent than ampho-
tericin B (MIC = 25–50 lg mL1) [33].
According to Rajanarendar and coworkers [40], isaxole
Biginelli adducts are promising antifungal agents against A.
niger, Chrysosporium tropicum, Rhizopusoryzae, Fusarium mon-
iliformae and Curvularia lunata. When tested at 100 lg mL1,
compounds 89 and 90 (Fig. 6) were able to induce the forma-
tion of a zone of fungal growth inhibition from 60 mm to
65 mm against the strains tested, which confers to these
compounds higher potency in comparison with clotrimazole
(inhibition zone of up to 35 mm) [40]. Studies of formation
of zones of fungal growth inhibition were also carried out with
C. albicans and Aspergillus parasiticus and the adducts 91–93
(Fig. 6) [41]. An average zone of inhibition of 16.5 mm was
veriﬁed in cultures of C. albicans in the presence of BiginelliN
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R5 = CH3, R6 = H, R7 = OH and R8 = OCH3 (105)
scavenge oxygen and/or nitrogen reactive species.
Biginelli adducts and biological activities 371adducts at 10 lg mL1, while clotrimazole triggered the
formation of a 21 mm-inhibition zone. As for A. parasiticus,
the inhibition zone in the presence of compounds 91–93 and
clotrimazole (all at 10 lg mL1) were, respectively, 13 mm,
17 mm, 18 mm and 22 mm [41].
Antioxidant activity
Oxygen and nitrogen reactive species (ROS and RNS, respec-
tively) are ubiquitous in nature being a result of electron
escape from electron transport chain (present in mitochondria
and chloroplast). The overproduction of ROS and/or RNS can
be deleterious to cells if the cellular antioxidant system is not
able to efﬁciently restore the normal levels, which can
ultimately cause pathologies [9,42].
The ﬁrst report on the antioxidant properties of Biginelli
adducts was published in 2006 in a study that investigated
the potential of such molecules to prevent ROS formation
and lipid peroxidation in male adult albino Wistar rats [42].
The Biginelli adducts 94 and 95 (Fig. 7) restored the lipid
hydroperoxide to normal levels in liver cells when administered
at 200 lM. These results indicate that the presence of a nitro
group on aromatic ring is not mandatory for adduct 95 pre-
venting lipid peroxidation. Compounds 94 and 96 (Fig. 7) were
found to be more efﬁcient than the corresponding nitro-ana-
logues 95 and 97 (Fig. 7) to prevent the overproduction of
ROS [42].
The potency of the thio-adducts 98 and 99 (87.5%; Fig. 7)
to scavenge hydroxyl radicals was comparable to that of the
reference antioxidant quercetol (92.3%) when all compounds
were used at 100 lM [43]. The thio-adducts 22 (Fig. 3) and
100 (Fig. 7) exhibit IC50 values of 10 lM and 76 lM,
respectively, regarding the scavenging of 2,2-diphenyl-1-pic-
rylhydrazyl (DPPH) radicals [44]. Also, compounds 22 and
100 at 300 lM diminished, at similar extents, the lipid
hydroperoxide levels in homogenates of cerebral cortex from
rats [44].
The adduct 101 (Fig. 7) effectively scavenged DPPH
radicals exhibiting an IC50 value of 0.6 mg mL
1, while the
IC50 value for gallic acid (a known radical scavenger) was
0.8 lg mL1 [45].
A series of Biginelli adducts were tested by da Silva and
coworkers to compare the ability of thio- and oxo-derivatives
to scavenge RNS and ROS [9]. Compounds 19, 21, 25
(Fig. 3) and 102 (Fig. 7) were determined to be the most
promising RNS scavengers among the tested adducts, as they
showed IC50 values of 20.3, 29.7, 23.3 and 24.2 lM,
respectively, while resveratrol exhibited an IC50 of 34.4 lM
in reactions containing DPPH 100 lM. As for ROS scaveng-
ing, the IC50 values for 19, 21, 25 and 102 and resveratrol
toward O2
 were 33.0, 25.7, 122.3, 78.0, 121.4 lM, respectively
[9].
Compounds 20 (Fig. 3) and 103–105 (Fig. 7) were
demonstrated to be as efﬁcient as gallic acid in the scavenging
of DPPH at 40 lg mL1 as the IC50 values for these adducts
ranged from 2.1 to 5.0 lg mL1 [46].
Concluding remarks
The diverse biological proﬁle of Biginelli adducts brought
perspectives for the development of novel drugs to improvehuman and animal health. Here, we compiled the effect of over
100 Biginelli adducts on cancer cells, calcium channels, inﬂam-
mation, microorganisms (bacteria, viruses and fungi) and ROS
and RNS scavenging. Some progress has been made with
respect to the mechanism of action by which monastrol (1)
and related molecules trigger the inhibition of cancer cells
growth. However, the mechanisms of action of Biginelli
adducts that lead to the attenuation and/or prevention of other
pathologies are still incipient. Therefore, advances in this
matter will certainly contribute to the rational design of more
efﬁcient and selective calcium channel inhibitor, anti-inﬂam-
matory, antimicrobial and antioxidant agents based on
Biginelli adducts core.Conﬂict of interest
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